CVCT’s Current Major Project
CVCT’s first project is a cellular vaccine currently being developed by Coventry-based researchers Dr John Maudsley and Dr Sarah Maudsley. They pioneered work on cell-based vaccines and were among the first to identify that cells from someone other than the patient could be more effective than the patient’s own cells. This idea has been taken up by researchers elsewhere in the world including in the US and Europe.
Stocks of the Maudsley vaccine have been manufactured and regulatory approvals are in place for the first clinical trial in cancer patients, focusing in particular on pancreatic cancer
The vaccine is being tested in its first clinical trial in the UK focusing in particular on Pancreatic Cancer which has extremely bleak outcome even with currently available treatment. Full details of the Trial can be found here: Clinical Trial of the Maudsley Vaccine – ACIT-1
Working with scientists, clinicians and other experts around the UK the trial has been designed to show the safety of the vaccine and identify the best dose or dose range for generating a specific immune response. The data generated will be important for designing future trials in other cancers enabling the right dose and treatment regime to be chosen.
Donated funds are being used to facilitate an increase in the amount of valuable data that can be obtained from patient samples, treat more patients and a greater range of cancer types.